The American Journal of Managed Care

Patient Response to Pirfenidone, Nintedanib for IPF Differs in Real World vs Trials

While both drugs slowed down lung function decline in idiopathic pulmonary fibrosis (IPF), they were also linked to more deaths and increased incidence of acute exacerbation of IPF in real-world ...
The American Journal of Managed Care

Key Predictors of Survival in IPF: Findings From the IPF-PRO Registry

The study aimed to identify predictors of long-term survival in idiopathic pulmonary fibrosis using the IPF-PRO Registry data. A retrospective cohort design was used, analyzing clinical, demographic, ...
Nasdaq

IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution?

LA JOLLA, CA / ACCESSWIRE / September 1, 2023 / Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the ...
Business Wire

PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...
FierceBiotech

PureTech shows durability of pulmonary fibrosis candidate, plots phase 3 trial

One day after Boehringer Ingelheim presented so-so data from a successful trial of its highly touted idiopathic pulmonary fibrosis (IPF) candidate nerandomilast, PureTech has answered with results ...